ImmuDyne Inc (OTCMKTS:IMMD) Is Now A Marketing Machine

ImmuDyne Inc (OTCMKTS:IMMD) is up nearly 200% month to date, and is coming off the back of a few major early 2017 catalysts. This is a company that has basically sat in and around the same price for twelve months or more. The company's rocketing from $0.25 to its current $0.8, for us, hints at a fundamental sentiment shift, and one that – in turn – suggests there's some longer term growth potential here.So, with that as a base, here's a look at the business update and what we want to see going forward as supportive of our longer term bull thesis.Immudyne is a healthcare stock based out of New York that has developed a range of products rooted in a scientific compound called a beta glucan. These are naturally occurring polysaccharides that are found in the cell walls of cereals, yeast, bacteria, and fungi, and there's a wealth of data to suggest that they have various health benefits for humans, when formulated in certain ways.We're not going to go into the science, or the data that supports its validity, in too much detail here. Sure, that the products work as advertised is important, but we're not looking at FDA regulated drugs or anything like that. These are OTC health and wellness products. In our eyes, it's more about marketing than it is about data – something we'll come back to shortly.So what did the latest business update tell us?Well, the company had a pretty solid 2016. It's share price across the period doesn’t really reflect this, but the milestones do. Specifically, the company was able to scale its direct to consumer skincare line from nothing to over $4.0M in top-line revenue. Just as importantly, it managed to do so with very little dilution to shareholders – circa $500k in outside investment raised at $0.23 per share. Management also reported the development of a superior formulation for its OTC line, and the signing of a couple of new endorsement deals, one of which saw it in-license a patented hair loss shampoo and conditioner from two guys –Dr. Steven Shapiro and Dr. Michael Borenstein – who are reportedly opinion leading dermatologists in Florida. Opinion leading in what sense, we're not sure, but it's a nice name to attach to a product that's going to launch next quarter.The company also commissioned a study that demonstrated that its core ingredient, the above mentioned beta glucans, have a positive effect on Langerhans cell (these are the dendritic cells of the skin) activity, as well as protecting skin from UV rays and pollutants. As we said, this latter data collection is really only important for us in terms of how the data transfers to a sound byte for marketing, and in this case, it transfers pretty well.Anyway, that's last year. What we're really interested in is the company's taking over of its own marketing platform. Its in-house team, called ImmuDyne PR, which reportedly includes 10 employees and a call center operation, is (as per management's latest communication) going to reduce customer acquisition costs by nearly 50% from 2016 levels. We've said it twice already, and we'll say it again – this company is now all about marketing. It's got a solid product base and it's got a fresh range about to launch, and value over the coming twelve months is going to be dictated by how effectively the company can put the cash it's got to use in acquiring customers. Management seems to understand this, and has proven it can allocate efficiently already (and the in-house team should improve further on this efficiently).Looking at the numbers, the company was able to grow top line from $714K to $1.25 million between 2014 and 2015, and expects to report full year 2016 at $5 million. 2017 estimates put revenues at nearly $10 million. For reference, and even taking the latest run into consideration, the market currently values this company at just $27 million.We will be updating our subscribers as soon as we know more. For the latest updates on IMMD, sign up below!Disclosure: We have no position in IMMD and have not been compensated for this article.